Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

Medical device company raises $87M to study new-look scaffolds for BTK PAD
R3 Vascular also announced that Christopher M. Owens, a veteran of the medical device industry, is its new president and CEO.
Radial vs. femoral access during PCI: Real-world data show proof of a ‘sea change’ in cardiology
The use of radial access during PCI procedures is increasing throughout the United States, and new data presented at the SCAI's annual meeting suggest that could be beneficial for patients.
FDA approves Abbott’s resorbable stent for BTK arteries
The bioresorbable stent, examined at length for the LIFE-BTK clinical trial, stays in place for up to three years before completely dissolving.
FDA clears new catheter for peripheral blood clots
The new-look catheter came out of a medical device incubator started by entrepreneur Eitan Konstantino, PhD, who has years of experience in the vascular space.
Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation
The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky.

Merative Merge Hemo being demonstrated to attendees at the America College of Cardiology (ACC) 2023 meeting. The system was ranked the best hemodynamic system by end-users in the 2023 "Best in KLAS" ratings. Photo by Dave Fornell

Best in KLAS 2024: New rankings for cardiovascular information systems, hemodynamic solutions

Hospital end users ranked the CVIS and hemodynamic systems they use, shedding light on their working relationships with IT vendors.

February 8, 2024

FDA approved the first transcatheter tricuspid valve (TTVR) replacement device in February 2024, the EVOQUE system from Edwards Lifesciences. The Evoque is the first transcatheter tricuspid valve approved by the FDA. The Evoke the first transcatheter tricuspid cleared in the United States.

Edwards makes history, receives FDA approval for transcatheter tricuspid valve replacement device

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation.

February 2, 2024

money business cash flow dollar. Kingsway Financial Services, a Chicago-based holding company with subsidiaries in several industries, has acquired New Jersey-based Digital Diagnostics Imaging (DDI) for $11 million. The transaction was funded with $5.4 million in cash and $5.6 million in debt financing.

FFR-guided PCI linked to significant cost savings

Researchers tracked data from more than 500 PCI patients, exploring the cost-effectiveness and safety of multiple treatment options.

January 25, 2024

Samin Sharma, MD, director of interventional cardiology and director of clinical cardiology, Mount Sinai Hospital, New York, discusses the first-in-human use of the Magenta Elevate percutaneous left ventricular assist device (pLVAD) with a small 10 French size and 5.5 liters per minute of hemodynamic support.

Initial results promising for world's smallest percutaneous heart pump

A new 10 French percutaneous heart pump could help greatly reduce vascular complications and improve cardiogenic shock outcomes.

January 22, 2024

Regularly eating avocados is associated with a reduced risk of cardiovascular disease, according to a new study.

Fasting before cardiac catheterization may not be necessary—recommend a heart-healthy diet instead

“Patients can safely continue oral intake until the time of the procedure, improving their satisfaction and comfort without adverse events,” researchers wrote.

January 11, 2024

Occlutech, a Swedish medical device company focused on structural heart disease, received U.S. Food and Drug Administration (FDA) approval in January 2024 for its ASD occluder for the treatment of atrial septal defects (ASDs).

Occlutech gains FDA approval for occluder device for atrial septal defects

According to CEO Sabine Bois, a veteran of the medical device industry, this approval represents a "significant leap forward" in the company's commitment to heart patients.

January 8, 2024

Video of Yousif Ahmad, MD, Yale, discussing IVL advances and increased reinbursements

Tracking key advances in intravascular lithotripsy

Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology.

January 2, 2024

Ziad Ali, MD, explaines the impact of coronary intravascular lithotripsy (IVL) use in nodular and eccentric calcium morphologies at TCT 2023. IVL was found to produce better outcomes than atherectomy or high pressure balloons. #TCT #TCT2023 #TCT23 #IVL

IVL is safe and effective across all calcium morphologies, new research confirms

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

December 19, 2023

Cath Lab

Medical device company raises $87M to study new-look scaffolds for BTK PAD

Radial vs. femoral access during PCI: Real-world data show proof of a ‘sea change’ in cardiology

FDA approves Abbott’s resorbable stent for BTK arteries

FDA clears new catheter for peripheral blood clots

Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation